2-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfanyl]-1-(7-ethyl-1H-indol-3-yl)ethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: 2-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfanyl]-1-(7-ethyl-1H-indol-3-yl)ethanone
• 化学式: C₁₉H₁₉N₅OS
• 分子量: 365.5
• InChiKey: KWDAAOAPELRJRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] CARBONYL LINKED BICYCLIC HETEROARYL ANTIBIOTIC TOLERANCE INHIBITORS<br/>[FR] INHIBITEURS DE LA TOLÉRANCE AUX ANTIBIOTIQUES À BASE D'HÉTÉROARYLE BICYCLIQUE À LIAISON CARBONYLE
  申请人：SPERO THERAPEUTICS INC

  公开号：WO2016007837A1

  公开（公告）日：2016-01-14

  The disclosure provides compounds and pharmaceutical compositions of the compounds useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein Q is selected from (a), (b), (c) and (d). Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.